Cardlytics, Inc. (NASDAQ:CDLX) Receives $6.92 Consensus Target Price from Brokerages

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) has been given a consensus rating of "Hold" by the seven analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $6.92.

Several analysts recently issued reports on the stock. Bank of America lowered shares of Cardlytics from a "neutral" rating to an "underperform" rating and cut their target price for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Craig Hallum upgraded Cardlytics from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 6th. Northland Capmk downgraded Cardlytics from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 16th. Evercore ISI assumed coverage on shares of Cardlytics in a research report on Friday, October 11th. They issued an "in-line" rating and a $4.00 price target for the company. Finally, Lake Street Capital cut shares of Cardlytics from a "buy" rating to a "hold" rating and lowered their target price for the company from $18.00 to $5.00 in a research note on Thursday, August 8th.

Insiders Place Their Bets

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the transaction, the chief executive officer now directly owns 178,519 shares of the company's stock, valued at $687,298.15. This trade represents a 11.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Alexis Desieno sold 25,118 shares of the business's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the completion of the sale, the chief financial officer now owns 116,481 shares in the company, valued at approximately $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 68,691 shares of company stock valued at $237,767 in the last quarter. 4.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its stake in shares of Cardlytics by 6.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company's stock valued at $432,000 after purchasing an additional 1,774 shares during the last quarter. Canton Hathaway LLC raised its holdings in Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company's stock valued at $37,000 after buying an additional 2,200 shares during the period. Check Capital Management Inc. CA lifted its position in Cardlytics by 10.4% in the third quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company's stock worth $162,000 after buying an additional 4,775 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Cardlytics by 32.1% during the third quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company's stock worth $63,000 after buying an additional 4,796 shares during the period. Finally, Creative Planning increased its position in Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company's stock valued at $95,000 after acquiring an additional 7,721 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company's stock.

Cardlytics Stock Performance

NASDAQ:CDLX traded down $0.22 during trading hours on Friday, reaching $3.38. The company had a trading volume of 1,038,456 shares, compared to its average volume of 1,235,099. The firm has a market cap of $171.77 million, a price-to-earnings ratio of -0.55 and a beta of 1.61. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm's 50 day moving average price is $3.72 and its 200-day moving average price is $6.37. Cardlytics has a 52 week low of $2.89 and a 52 week high of $20.52.

Cardlytics (NASDAQ:CDLX - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.18. The company had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. Cardlytics's revenue was down 15.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.26) earnings per share. On average, analysts forecast that Cardlytics will post -1.72 EPS for the current year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.